MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 12-16-2024
Enzo Biochem Net Debt 2011-2026 | ENZ
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Enzo Biochem
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -51.3 M | -81.1 M | -16.6 M | -5.75 M | -39.3 M | -55.5 M | -59.7 M | -63.6 M | -66.1 M | -14.7 M | -16.9 M | -8.56 M | -15.1 M | -14.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -5.75 M | -81.1 M | -36.3 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
-6.88 M | $ 22.03 | 3.19 % | $ 99.4 M |  Israel |
 |
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
-76 M | $ 22.9 | 19.89 % | $ 246 M |  China |
 |
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | USA |
 |
BioNano Genomics
BNGO
|
-2.64 M | $ 1.6 | -0.62 % | $ 2.03 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M |  Britain |
 |
Co-Diagnostics
CODX
|
-11.9 M | $ 6.05 | 6.14 % | $ 178 M | USA |
 |
Castle Biosciences
CSTL
|
-108 M | $ 40.8 | 1.83 % | $ 1.13 B | USA |
 |
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | USA |
 |
Danaher Corporation
DHR
|
13.6 B | $ 234.89 | -0.73 % | $ 172 B | USA |
 |
DarioHealth Corp.
DRIO
|
-12.1 M | $ 12.11 | -10.18 % | $ 344 M | Israel |
 |
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M | China |
 |
DexCom
DXCM
|
-487 M | $ 70.15 | 0.37 % | $ 27.1 B | USA |
 |
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-560 M | $ 101.62 | -0.03 % | $ 18.8 B | USA |
 |
CareDx, Inc
CDNA
|
-48 M | $ 18.99 | 0.96 % | $ 1.02 B | USA |
 |
Fulgent Genetics
FLGT
|
-53.3 M | $ 27.97 | 7.62 % | $ 846 M | USA |
 |
Celcuity
CELC
|
82.8 M | $ 109.72 | 4.47 % | $ 4.33 B | USA |
 |
Anixa Biosciences
ANIX
|
-1.04 M | $ 3.26 | 2.4 % | $ 104 K | USA |
 |
Guardant Health
GH
|
646 M | $ 110.12 | -1.97 % | $ 13.5 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
2.48 B | $ 29.05 | 1.22 % | $ 20 B |  Niderland |
 |
Aspira Women's Health
AWH
|
-10.9 M | - | -6.19 % | $ 10.5 M | USA |
 |
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | USA |
 |
IQVIA Holdings
IQV
|
11.2 B | $ 244.09 | 1.5 % | $ 44.3 B | USA |
 |
Illumina
ILMN
|
-494 M | $ 151.07 | 2.65 % | $ 24 B | USA |
 |
Charles River Laboratories International
CRL
|
2.1 B | $ 216.28 | - | $ 11.1 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
5.24 B | $ 178.22 | -1.22 % | $ 19.8 B | USA |
|
Biodesix
BDSX
|
14.5 M | $ 5.86 | -2.82 % | $ 760 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
4 B | $ 253.83 | -2.49 % | $ 21.3 B | USA |
 |
Motus GI Holdings
MOTS
|
-3.55 M | - | -34.28 % | $ 263 K | Israel |
 |
ICON Public Limited Company
ICLR
|
4.63 B | $ 202.64 | 0.58 % | $ 16.7 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
183 M | $ 710.27 | 0.49 % | $ 58.6 B | USA |
 |
Lantheus Holdings
LNTH
|
-346 M | $ 69.22 | -0.66 % | $ 4.79 B | USA |
 |
Agilent Technologies
A
|
1.24 B | $ 147.47 | -0.1 % | $ 44.8 B | USA |
 |
Biomerica
BMRA
|
-1.94 M | $ 2.78 | 5.41 % | $ 6.39 M | USA |
 |
Bioventus
BVS
|
334 M | $ 7.56 | -1.18 % | $ 474 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-11.6 M | - | - | $ 9.42 M | Israel |
 |
QIAGEN N.V.
QGEN
|
1.31 B | $ 47.23 | 0.32 % | $ 10.5 B | Niderland |
 |
Mettler-Toledo International
MTD
|
1.8 B | $ 1 462.87 | -1.54 % | $ 31 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
115 M | $ 6.7 | 2.68 % | $ 607 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-4.37 M | $ 4.51 | -1.96 % | $ 2.42 M | USA |
 |
NeoGenomics
NEO
|
-23.3 M | $ 12.69 | -0.78 % | $ 1.61 B | USA |